African Regional Intellectual Property Organization

Three Sixty Solar Receives Positive Review of Technology Patentability

Retrieved on: 
Thursday, January 26, 2023
File, Three Sixty, Engineering, African Regional Intellectual Property Organization, OTC, NEO, World Intellectual Property Organization, Union, Patent, PCT, ARIPO, 3D printing, Pharmaceutical industry

Brian Roth, CEO of Three Sixty Solar states, “I’m very encouraged by this positive response from ARIPO.

Key Points: 
  • Brian Roth, CEO of Three Sixty Solar states, “I’m very encouraged by this positive response from ARIPO.
  • Three Sixty Solar has received notification from ARIPO that the organization has completed their initial review of the Company’s patent application.
  • According to their review, the four primary claims that differentiate Three Sixty Solar’s technology all pass the three tests for patentability; the claims are novel, inventive, and have industrial applicability.
  • The Company is encouraged that the US PTO and other patent offices will reach the same positive conclusion as ARIPO regarding patentability of the primary claims.

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Retrieved on: 
Tuesday, April 26, 2022
Patent, African Regional Intellectual Property Organization, Idiopathic pulmonary fibrosis, Pioglitazone, COVID-19, USPTO, PPAR, Patient, GI, United States Patent and Trademark Office, United States patent law, Philip Key (U.S. politician), MAPK, Method, IP, Lung cancer, Ovarian cancer, Pharmaceutical industry, Cancer, Muthiri kinaru, ARIPO

Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate

Key Points: 
  • Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
    Grant of KIN001 composition of matter patent strengthens proprietary position in U.S. until at least 2037
    Basel, Switzerland, April 26, 2022.
  • Kinarus AG ('Kinarus') announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No.
  • 11285155 entitled "Pharmaceutical Combinations for Treating Cancer" that covers the Kinarus lead therapeutic candidate KIN001.
  • Kinarus' differentiated therapeutic candidate, KIN001, has broad potential in numerous therapeutic areas.